SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice

References

• Goldstone DC, Ennis-Adeniran V, Hedden JJ, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480(7377):379–382. PubMed PMID: 22056990.
   PubMed Web of Science ®Google Scholar
• Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–661. PubMed PMID: 21720370; PubMed Central PMCID:PMC3179858.
   PubMed Web of Science ®Google Scholar
• Franzolin E, Pontarin G, Rampazzo C, et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A. 2013;110(35):14272–14277. PubMed PMID: 23858451; PubMed Central PMCID:PMC3761606.
   PubMed Web of Science ®Google Scholar
• Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–657. PubMed PMID: 21613998; PubMed Central PMCID:PMC3595993.
   PubMed Web of Science ®Google Scholar
• Powell RD, Holland PJ, Hollis T, et al. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem. 2011;286(51):43596–43600. PubMed PMID: 22069334; PubMed Central PMCID:PMC3243528.
   PubMed Web of Science ®Google Scholar
• Kohnken R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Mol Cancer. 2015;14:176. PubMed PMID: 26416562; PubMed Central PMCID:PMC4587406.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. PubMed PMID: 22810696; PubMed Central PMCID:PMC3401966.
   PubMed Web of Science ®Google Scholar
• Clifford R, Louis T, Robbe P, et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood. 2014;123(7):1021–1031. PubMed PMID: 24335234; PubMed Central PMCID:PMC3924925.
   PubMed Web of Science ®Google Scholar
• Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191–4196. PubMed PMID: 22915640.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734. PubMed PMID: 21941284; PubMed Central PMCID:PMC3307543.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806. PubMed PMID: 18772397; PubMed Central PMCID:PMC2848990.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. PubMed PMID: 18772396; PubMed Central PMCID:PMC2820389.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435–439. PubMed PMID: 21163964; PubMed Central PMCID:PMC3110744.
   PubMed Web of Science ®Google Scholar
• Liu J, Lee W, Jiang Z, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315–2327. PubMed PMID: 23033341; PubMed Central PMCID:PMC3514662.
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726. PubMed PMID: 23415222; PubMed Central PMCID:PMC3575604.
   PubMed Web of Science ®Google Scholar
• Rentoft M, Lindell K, Tran P, et al. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proc Natl Acad Sci U S A. 2016;113(17):4723–4728. PubMed PMID: 27071091; PubMed Central PMCID:PMC4855590.
   PubMed Web of Science ®Google Scholar
• Daddacha W, Koyen AE, Bastien AJ, et al. SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination. Cell Rep. 2017;20(8):1921–1935. PubMed PMID: 28834754; PubMed Central PMCID:PMC5576576.
   PubMed Web of Science ®Google Scholar
• Herold N, Rudd SG, Sanjiv K, et al. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle. 2017;16(11):1029–1038. PubMed PMID: 28436707; PubMed Central PMCID:PMC5499833.
   PubMed Web of Science ®Google Scholar
• Wang JL, Lu FZ, Shen XY, et al. SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation. Biochem Biophys Res Commun. 2014;455(3–4):229–233. PubMed PMID: 25449277.
   PubMed Web of Science ®Google Scholar
• de Silva S, Hoy H, Hake TS, et al. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J Biol Chem. 2013;288(13):9284–9292. PubMed PMID: 23426363; PubMed Central PMCID:PMC3610999.
   PubMed Web of Science ®Google Scholar
• Kohnken R, Kodigepalli KM, Mishra A, et al. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sezary syndrome patients. Leuk Res. 2017;52:58–66. PubMed PMID: 27889686; PubMed Central PMCID:PMC5195900.
   PubMed Web of Science ®Google Scholar
• de Silva S, Wang F, Hake TS, et al. Downregulation of SAMHD1 expression correlates with promoter DNA methylation in Sezary syndrome patients. J Invest Dermatol. 2014;134(2):562–565. PubMed PMID: 23884314; PubMed Central PMCID:PMC3844041.
   PubMed Web of Science ®Google Scholar
• Kodigepalli KM, Li M, Liu SL, et al. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. Cell Cycle. 2017;16(2):179–188. PubMed PMID: 27929746; PubMed Central PMCID:PMC5283819.
   PubMed Web of Science ®Google Scholar
• Kodigepalli KM, Bonifati S, Tirumuru N, et al. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle. 2018;17(9):1124–1137. PubMed PMID: 29911928.
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–644. PubMed PMID: 19644473; PubMed Central PMCID:PMC3142564.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203. PubMed PMID: 22358332.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562. PubMed PMID: 19629070.
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819–828. PubMed PMID: 19951971; PubMed Central PMCID:PMC2864389.
   PubMed Web of Science ®Google Scholar
• Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 2015;3:2. PubMed PMID: 26056603; PubMed Central PMCID:PMC4452048.
   PubMedGoogle Scholar
• Lindblad O, Cordero E, Puissant A, et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. 2016;35(39):5119–5131. PubMed PMID: 26999641; PubMed Central PMCID:PMC5399143.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chiarini F, et al. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010;1(2):89–103. PubMed PMID: 20671809; PubMed Central PMCID:PMC2911128.
   PubMedGoogle Scholar
• Polivka J Jr., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164–175. PubMed PMID: 24333502.
   PubMed Web of Science ®Google Scholar
• Bortul R, Tazzari PL, Billi AM, et al. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol. 2005;129(5):677–686. PubMed PMID: 15916691.
   PubMed Web of Science ®Google Scholar
• Sampath D, Cortes J, Estrov Z, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107(6):2517–2524. PubMed PMID: 16293603; PubMed Central PMCID:PMC1895741.
   PubMed Web of Science ®Google Scholar
• Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 2002;21(11):1727–1738. PubMed PMID: 11896604.
   PubMed Web of Science ®Google Scholar
• Diehl N, Schaal H. Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway. Viruses. 2013;5(12):3192–3212. PubMed PMID: 24351799; PubMed Central PMCID:PMC3967167.
   PubMed Web of Science ®Google Scholar
• Allen TE, Sherrill KJ, Crispell SM, et al. The jaagsiekte sheep retrovirus envelope gene induces transformation of the avian fibroblast cell line DF-1 but does not require a conserved SH2 binding domain. J Gen Virol. 2002;83(Pt 11):2733–2742. PubMed PMID: 12388809.
   PubMedGoogle Scholar
• Maeda N, Palmarini M, Murgia C, et al. Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci U S A. 2001;98(8):4449–4454. PubMed PMID: 11296288; PubMed Central PMCID:PMC31855.
   PubMed Web of Science ®Google Scholar
• Rai SK, Duh FM, Vigdorovich V, et al. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci U S A. 2001;98(8):4443–4448. PubMed PMID: 11296287; PubMed Central PMCID:PMC31854.
   PubMed Web of Science ®Google Scholar
• Zavala G, Pretto C, Chow YH, et al. Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep retrovirus. Virology. 2003;312(1):95–105. PubMed PMID: 12890624.
   PubMed Web of Science ®Google Scholar
• Johnson C, Sanders K, Fan H. Jaagsiekte sheep retrovirus transformation in Madin-Darby canine kidney epithelial cell three-dimensional culture. J Virol. 2010;84(10):5379–5390. PubMed PMID: 20219922; PubMed Central PMCID:PMC2863794.
   PubMed Web of Science ®Google Scholar
• Liu SL, Miller AD. Transformation of madin-darby canine kidney epithelial cells by sheep retrovirus envelope proteins. J Virol. 2005;79(2):927–933. PubMed PMID: 15613321; PubMed Central PMCID:PMC538587.
   PubMed Web of Science ®Google Scholar
• Bonifati S, Daly MB, St Gelais C, et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology. 2016;495:92–100. PubMed PMID: 27183329; PubMed Central PMCID:PMC4912869.
   PubMed Web of Science ®Google Scholar
• Ross TM, Minella AC, Fang ZY, et al. Mutational analysis of human T-cell leukemia virus type 2 Tax. J Virol. 1997;71(11):8912–8917. PubMed PMID: 9343258; PubMed Central PMCID:PMC192364.
   PubMed Web of Science ®Google Scholar
• Wang F, St Gelais C, de Silva S, et al. Phosphorylation of mouse SAMHD1 regulates its restriction of human immunodeficiency virus type 1 infection, but not murine leukemia virus infection. Virology. 2016;487:273–284. PubMed PMID: 26580513; PubMed Central PMCID:PMC4679491.
   PubMed Web of Science ®Google Scholar
• Wu L. SAMHD1 knockout mice: modeling retrovirus restriction in vivo. Retrovirology. 2013;10:142. PubMed PMID: 24257155; PubMed Central PMCID:PMC3842632.
   PubMed Web of Science ®Google Scholar
• St Gelais C, de Silva S, Hach JC, et al. Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1. J Virol. 2014;88(10):5834–5844. PubMed PMID: 24623419; PubMed Central PMCID:PMC4019113.
   PubMed Web of Science ®Google Scholar
• Buzovetsky O, Tang C, Knecht KM, et al. The SAM domain of mouse SAMHD1 is critical for its activation and regulation. Nat Commun. 2018;9(1):411. PubMed PMID: 29379009; PubMed Central PMCID:PMC5788916.
   PubMedGoogle Scholar
• Zhang R, Bloch N, Nguyen LA, et al. SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells. PLoS One. 2014;9(2):e89558. PubMed PMID: 24586870; PubMed Central PMCID:PMC3929709.
   PubMed Web of Science ®Google Scholar
• Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13(3):223–228. PubMed PMID: 22327569; PubMed Central PMCID:PMC3771401.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. PubMed PMID: 26660429; PubMed Central PMCID:PMC4705610.
   PubMed Web of Science ®Google Scholar
• Schneider C, Oellerich T, Baldauf HM, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23(2):250–255. PubMed PMID: 27991919.
   PubMed Web of Science ®Google Scholar
• Herold N, Rudd SG, Ljungblad L, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23(2):256–263. PubMed PMID: 28067901.
   PubMed Web of Science ®Google Scholar
• Herold N, Rudd SG, Sanjiv K, et al. With me or against me: tumor suppressor and drug resistance activities of SAMHD1. Exp Hematol. 2017;52:32–39. PubMed PMID: 28502830.
   PubMed Web of Science ®Google Scholar